# US 2023/0263901 A1 · Mucus adhesion drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263901 A1
- Document ID: US20230263901A1
- Status: Published application
- Kind: A1
- Application number: 18/040,315
- Filed: 2021-01-29
- Published: 2023-08-24
- Earliest claimed: 2021-01-29
- Inventors: Yimin Sun
- Web page: https://patentgrep.com/patent/US20230263901A1

## CPC

- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 9/146: {with organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a mucus adhesion drug delivery technology. The technology involves the preparation of materials consisting of mucus adhesive excipient polymer chemically bonded with drug molecules and delivery of the materials with fast disintegration tablet with enteric coating to intestine. The bonding between the excipient polymer and the drug molecules is either ionic bonds, covalent bonds, or metal coordination bonds. The test of the mucus adhesion drug delivery technology was carried out using a dog model. The test data indicated successful retaining of drug molecules on the intestine mucus resulting in not only dramatic extension of drug release time, but also great improvement in the bioavailability of the API.

## Claims

### Claim 1

A composition comprising an effective amount of a biologically active agent bonded with a mucoadhesive polymer ionically or covalently or via metal coordination bonding, whereby after the composition is administered to a subject, the biologically active agent exerts its pharmaceutical effect while retaining on mucus of the animal.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the effective amount of biologically active agent bonded with a mucoadhesive polymer ionically or covalently or via metal coordination bonding is compressed into tablets with at least one excipient, and the tablets are coated with an enteric coating material so that the pharmaceutically active compound is gradually released in an intestine of the subject and absorbed through an intestine wall into blood stream of the subject in presence of NaCl or other ionic compound or via hydrolysis in the body fluid of the subject.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the biologically active agent comprises at least one functional group selected from the group consisting of amine, carboxyl, hydroxyl, sulfonic functional group —SO3H, cationic metal, and combinations thereof, and the mucoadhesive polymer comprises at least one corresponding functional group selected from the consisting of carboxyl, hydroxyl, amine, sulfonic functional group —SO3H, and combinations thereof so that the pharmaceutically active compound is bonded with the mucoadhesive polymer ionically or covalently or via metal coordination.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the biologically active agent is ionically bonded with the mucoadhesive polymer, and the pharmaceutically active compound is released in the body of the animal via metastasis.

### Claim 5 (depends on 4)

The composition of claim 4 wherein the biologically active agent comprises at least one functional group selected from the group consisting of amine, carboxyl, sulfonic functional group —SO3H, and combinations, and the mucoadhesive polymer comprises at least one corresponding functional group selected from the consisting of carboxyl, amine, sulfonic functional group —SO3H, and combinations.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the biologically active agent is covalently bonded with the mucoadhesive polymer, and the pharmaceutically active compound is released in the body of the animal via hydrolysis.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the mucoadhesive polymer is selected from the group consisting of poly(methylvinylether co-methacrylic acid), poly(acrylic acid-co ethylhexylacrylate), copolymer of acrylic acid and poly ethylene glycolpolymer, copolymer of acrylic acid or methacrylic acid, carbopol, polycarbophil, carbomer, pectin, alginic acid, hyaluronic acid, chitosan, tragacanth gum, karaya gum, xanthan gum, carboxymethylcellulose, polyvinylamine, polyallylamine, polyethyleneimine, and combinations thereof.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the biologically active agent is selected from the group consisting of ibuprofen, lanthnum chloride, levodopa ethyl ester, aspirin, glutathione, valsartan, quetiapine, duloxetine, oxymorphone, and combinations thereof.

### Claim 9 (depends on 1)

The composition of claim 1 comprising less than 50% by molar amount of the biologically active agent in free form relative to the biologically active agent bonded with the mucoadhesive polymer by molar amount.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the mucus adhesive materials bonded with drug molecules has a diameter of less than 3 mm.

### Claim 11 (depends on 1)

The composition of claim 1 comprising no greater than 30% by molar amount of the biologically active agent in free form relative to the biologically active agent bonded with the mucoadhesive polymer by molar amount.

### Claim 12 (depends on 1)

The composition of claim 1 wherein the biologically active agent has a half-life of no greater than 2 hours or a bioavailability of less than 80% due to missing out absorption window of GI tract, and the composition has an extended time of delivery of the biologically active agent for more than 12 hours.

### Claim 13 (depends on 1)

The composition of claim 1 being formulated in a solid dosage form.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the solid dosage form is a fast disintegration form and further comprises a non-ionic filler excipient and a disintegrant.

### Claim 15 (depends on 1)

A method of extending release time of a biologically active agent and increase bioavailability of the biologically active agent in a subject comprising:
preparing the composition of claim 1; and
administering the composition to a subject in an effective amount.

### Claim 16 (depends on 1)

The method of claim 1 wherein the administering comprising delivering the composition through mucosa of mouth, nose, stomach, intestine, and/or or eye of the subject.

### Claim 17 (depends on 1)

A method of making the composition of claim 1 comprising:
reacting an effective amount of the biologically active agent with mucoadhesive polymer in water or a non-aqueous solvent via acid-base reaction, metathesis reaction, or esterification reaction to make the pharmaceutically active compound bonded with the mucoadhesive polymer.
